Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment.

Valikhani, Mohsen; Rahimian, Elahe; Ahmadi, Seyed Esmaeil; Chegeni, Rouzbeh; Safa, Majid

Valikhani, Mohsen; Rahimian, Elahe; Ahmadi, Seyed Esmaeil; Chegeni, Rouzbeh; Safa, Majid.

Afiliación

Valikhani M; Department of Hematology and Blood Banking, Faculty of Allied Medicine, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Rahimian E; Department of Medical Translational Oncology, National Center for Tumor Diseases (NCT) Dresden, Dresden, Germany.
Ahmadi SE; Department of Hematology and Blood Banking, Faculty of Allied Medicine, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Chegeni R; Medical Laboratory Sciences, Program, College of Health and Human Sciences, Northern Illinois University, DeKalb, IL, USA.
Safa M; Department of Hematology and Blood Banking, Faculty of Allied Medicine, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. safa.m@iums.ac.ir.

Exp Hematol Oncol ; 10(1): 51, 2021 Nov 03.

Article en En | MEDLINE | ID: mdl-34732266

Palabras clave

Alternative end-joining pathways; Double-strand break; Double-strand break repair; Hematologic malignancies; Non-homologous end-joining; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2021 Tipo del documento: Article País de afiliación: Irán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Exp Hematol Oncol Año: 2021 Tipo del documento: Article País de afiliación: Irán